However, several clinical trials have evaluated immune checkpoint inhibitors in advanced NSCLC, including CheckMate026 trial, a phase III study comparing nivolumab to platinum-based chemotherapy in treatment-naïve advanced NSCLC patients with low PD-L1 expression levels failed to demonstrate clinical benefit [104]. Here, CD274 is linked to non-small cell lung carcinoma.